MedTrace Logo

A Study To Evaluate The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of PF-03882845 In Healthy Volunteers

NCT00971802 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2010-02-23

No results posted yet for this study

Summary

To evaluate the safety and tolerability of PF-03882845 in Healthy Volunteers. To evaluate the pharmacokinetics of PF-03882845 in Healthy Volunteers. To evaluate the pharmacodynamics of PF-03882845 in Healthy Volunteers.

Conditions

  • Healthy Volunteers

Interventions

DRUG

PF-03882845 or Placebo

PF-03882845 20 mg or Placebo, daily for 10 days.

DRUG

PF-03882845 or Placebo

PF-03882845 60 mg or Placebo, daily for 10 days.

DRUG

PF-03882845 or Placebo

PF-03882845 120 mg or Placebo, daily for 10 days.

DRUG

PF-03882845 or Placebo

PF-03882845 185 mg or Placebo, daily for 10 days.

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2009-09-30
Primary Completion
2010-02-28
Completion
2010-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00971802 on ClinicalTrials.gov